Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1964 1
1965 6
1966 13
1967 12
1968 18
1969 21
1970 12
1971 14
1972 11
1973 9
1974 11
1975 8
1976 7
1977 10
1978 7
1979 10
1980 5
1981 7
1982 9
1983 4
1984 8
1985 11
1986 12
1987 9
1988 6
1989 6
1990 12
1991 9
1992 5
1993 7
1994 9
1995 10
1996 23
1997 16
1998 18
1999 16
2000 23
2001 15
2002 16
2003 23
2004 20
2005 24
2006 37
2007 35
2008 38
2009 31
2010 41
2011 57
2012 39
2013 47
2014 47
2015 59
2016 51
2017 52
2018 43
2019 23
2020 4
Text availability
Article attribute
Article type
Publication date

Search Results

1,010 results
Results by year
Filters applied: . Clear all
Page 1
Ruxolitinib.
Ajayi S, Becker H, Reinhardt H, Engelhardt M, Zeiser R, von Bubnoff N, Wäsch R. Ajayi S, et al. Recent Results Cancer Res. 2018;212:119-132. doi: 10.1007/978-3-319-91439-8_6. Recent Results Cancer Res. 2018. PMID: 30069628
Developmental Therapeutics in Myeloproliferative Neoplasms.
Bose P, Verstovsek S. Bose P, et al. Clin Lymphoma Myeloma Leuk. 2017 Jul;17S:S43-S52. doi: 10.1016/j.clml.2017.02.014. Clin Lymphoma Myeloma Leuk. 2017. PMID: 28760302 Free PMC article. Review.
Treatment of polycythemia vera.
Dulíček P. Dulíček P. Vnitr Lek. 2018 Fall;64(10):955-960. Vnitr Lek. 2018. PMID: 30590943 English.
Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study.
Passamonti F, Griesshammer M, Palandri F, Egyed M, Benevolo G, Devos T, Callum J, Vannucchi AM, Sivgin S, Bensasson C, Khan M, Mounedji N, Saydam G. Passamonti F, et al. Lancet Oncol. 2017 Jan;18(1):88-99. doi: 10.1016/S1470-2045(16)30558-7. Epub 2016 Dec 2. Lancet Oncol. 2017. PMID: 27916398 Clinical Trial.
A journey through infectious risk associated with ruxolitinib.
Sant'Antonio E, Bonifacio M, Breccia M, Rumi E. Sant'Antonio E, et al. Br J Haematol. 2019 Nov;187(3):286-295. doi: 10.1111/bjh.16174. Epub 2019 Aug 29. Br J Haematol. 2019. PMID: 31468506 Review.
Austrian recommendations for the management of polycythemia vera.
Burgstaller S, Buxhofer-Ausch V, Sliwa T, Beham-Schmid C, Gastl G, Geissler K, Melchardt T, Krauth M, Krippl P, Petzer A, Rumpold H, Wölfler A, Gisslinger H. Burgstaller S, et al. Wien Klin Wochenschr. 2018 Sep;130(17-18):535-542. doi: 10.1007/s00508-018-1359-3. Epub 2018 Jul 19. Wien Klin Wochenschr. 2018. PMID: 30027395 Review.
Ruxolitinib for the treatment of inadequately controlled polycythemia vera without splenomegaly: 80-week follow-up from the RESPONSE-2 trial.
Griesshammer M, Saydam G, Palandri F, Benevolo G, Egyed M, Callum J, Devos T, Sivgin S, Guglielmelli P, Bensasson C, Khan M, Ronco JP, Passamonti F. Griesshammer M, et al. Ann Hematol. 2018 Sep;97(9):1591-1600. doi: 10.1007/s00277-018-3365-y. Epub 2018 May 27. Ann Hematol. 2018. PMID: 29804268 Free PMC article. Clinical Trial.
Safety and efficacy of combination therapy of interferon-α2 and ruxolitinib in polycythemia vera and myelofibrosis.
Mikkelsen SU, Kjaer L, Bjørn ME, Knudsen TA, Sørensen AL, Andersen CBL, Bjerrum OW, Brochmann N, Fassi DE, Kruse TA, Larsen TS, Mourits-Andersen HT, Nielsen CH, Pallisgaard N, Thomassen M, Skov V, Hasselbalch HC. Mikkelsen SU, et al. Cancer Med. 2018 Aug;7(8):3571-3581. doi: 10.1002/cam4.1619. Epub 2018 Jun 22. Cancer Med. 2018. PMID: 29932310 Free PMC article. Clinical Trial.
1,010 results
Jump to page
Feedback